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Abstract
Alterations of Eph receptor tyrosine kinases are frequent events in human cancers. Genetic variations of EPHB6 have been
described but the functional outcome of these alterations is unknown. The current study was conducted to screen for the
occurrence and to identify functional consequences of EPHB6 mutations in non-small cell lung cancer. Here, we sequenced
the entire coding region of EPHB6 in 80 non-small cell lung cancer patients and 3 tumor cell lines. Three potentially relevant
mutations were identified in primary patient samples of NSCLC patients (3.8%). Two point mutations led to instable
proteins. An in frame deletion mutation (del915-917) showed enhanced migration and accelerated wound healing in vitro.
Furthermore, the del915-917 mutation increased the metastatic capability of NSCLC cells in an in vivo mouse model. Our
results suggest that EPHB6 mutations promote metastasis in a subset of patients with non-small cell lung cancer.
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Introduction
Lung cancer is a leading cause of cancer related death with
the majority of cases belonging to the group of non-small cell
lung cancer (NSCLC) [1,2]. Development of distant metastasis
is the major cause of NSCLC related death. Receptor tyrosine
kinases (RTKs) play important roles in the metastatic process
[3,4]. One of the best known RTK associated with a metastasis
phenotype, is the epidermal growth factor receptor (EGFR) with
its family members ERBB2/Her2, ERBB3 and ERBB4. RTKs
such as the EGFR family are therefore attractive targets for
improved molecular therapy approaches in cancers [3,5]. To
date, the Ephrin (EPH) receptor subfamily is the largest
subfamily of RTKs comprising of 16 members in vertebrates,
namely EPHA receptors 1–10 (EPHA1-A10) and EPHB
receptors 1–6 (EPHB1-B6) [6,7]. EPHB receptors interact with
the Ephrin family of ligands. Upon interaction with their Ephrin
ligands, EPH receptors modulate a variety of biological
activities, including cell-cell interaction and cell migration
[8,9]. Loss of the kinase-dead EPHB6 is associated with
advanced tumor stages and cancer progression [10–16]. Several
publications report on high EPHB6 expression being a favorable
prognostic marker in neuroblastoma [10–12]. In addition,
mRNA expression of EPHB6 was decreased in metastatic
melanoma and in invasive breast cancer cell lines with
metastatic potential [14–16]. Functionally, EPHB6 suppresses
invasiveness, growth rate and colony-forming efficiency of
cultured breast cancer cells [17–18], regulates cell adhesion
and affects migration [19].
Previously, we identified several human RTKs whose expres-
sion level correlated with the development of metastasis in early-
stage NSCLC [20]. Whereas high mRNA expression of several
RTKs was associated with an increased frequency of metastasis
development, high mRNA expression levels of the two RTKs
EPHB6 and DKFZ1 indicated a reduced risk for metastasis [20].
Recently, we identified EPHB6 as an epigenetically silenced
metastasis suppressor in NSCLC, and expression of EPHB6
prevented metastasis formation in a xenograft metastasis model
[21].
Here, we scrutinized the EPHB6 variation by DNA sequencing,
and characterized the functional consequences of EPHB6
mutations in vivo and in vitro with regard to their potential role in
NSCLC metastasis.
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Materials and Methods
Cell culture
The NSCLC cell lines involved in current study have been
described previously [21]. Briefly, A549 lung adenocarcinoma cells
were cultured at 37uC, high humidity and 5% CO2 in DMEM
(Dulbeccos Modified Eagle’s medium, Invitrogen, Carlsbad, CA).
The medium was supplemented with 10% fetal calf serum (FCS)
and 1% streptomycin and penicillin. HTB56 and HTB58 lung
adenocarcinoma cells were cultured at 37uC, high humidity, and
5% CO2 in MEM (Modified Eagle’s medium, Invitrogen,
Carlsbad. CA). The medium was supplemented with 10% FCS,
1% streptomycin and penicillin, 1% glutamine, 1% sodium
pyruvate, and 1% nonessential amino acid.Cell line identity was
confirmed by STR-genotyping.
Patient Specimens
Primary tumor specimens and tumor-free lung tissues were
obtained at the time of initial surgery from 80 patients with
histology-proven NSCLC at a University hospital in Germany.
Samples were immediately shock frozen and stored in liquid
nitrogen. The tumor samples were checked for the percentage
of tumor cells by histology, and only tumor biopsies with at
least 70% cancer cells were used for subsequent analyses.
Similarly, cancer-free control samples were also confirmed by
histological examination. All patients provided written consent
and the study was approved by the Ethics committee at the
University of Mu¨nster.
EPHB6 Sequencing
Genomic DNA was extracted using DNAzol (Invitrogen,
Carlsbad, CA, USA). Primers were designed with Primer3
software (DISTRIBUTOR) to amplify polymerase-chain-reaction
(PCR) fragments sized between 400 and 800 bps and covering the
complete coding region of the EPHB6 gene (details of PCR are
provided in Supplementary Material). All All fragments were
amplified by PCR with Taq DNA Polymerase (total reaction
volume 20 ml) supplemented with a home-made PCR enhancer as
described [22]. Both strands were sequenced utilizing the PCR
primers. Additional internal primers were used for PCR products
longer than 600 bp to ensure double-stranded sequence in-
formation for the whole PCR fragment. Sequencing was
performed on ABI3730xl automated DNA sequencers with the
BigDye Terminator V3.1 Cycle Sequencing Kit (Applied
Biosystems). The sequenced coding region of EPHB6 was
compared with the reference sequence (GenBank accession No.
NM_004445).
Site-directed Mutagenesis
The coding region of the human EPHB6 cDNA (base 833-3853
NCBI Accession No. NM_004445) was cloned into the pcDNA4
To/myc/hisA expression vector (Invitrogen, Carlsbad, CA, USA).
Mutations in the coding sequence of EPHB6 were introduced with
the QuickChange XL site-directed mutagenesis kit (Stratagene, La
Jolla, CA, USA) using primers with the sequences: forward (59-
AGGCTGGCGGGGAAAGGCCTTCCCAGG), reverse (59-
CCTGGGAAGGCCTTTCCCCGCCAGCCT) and using
pcDNA4-EPHB6 vector as the template. Afterwards, the correct
sequence was verified by sequencing. Primers for further
mutations will be provided upon request.
Expression Constructs and Transfection
Human A549 cells were co-transfected using the transfection
reagent Nanofectin (PAA, Austria) according to the manufac-
turer’s protocol. Co-transfection was carried out with either
pcDNA4 (empty vector control), wild type EPHB6 expression
construct (pcDNA4-EPHB6-wt) or EPHB6 mutant expression
constructs, each with an EGFP expressing vector construct
(pcDNA3.1-GFP, expressing enhanced green fluorescent protein
EGFP) for selection and identification of transfected cells.
Transfected cells were selected with 700 mg/ml G418 (Sigma,
St. Louis, MO, USA) and 400 mg/ml Zeocin (Invitrogen,
Carlsbad, CA, USA). Bulk cultures were FACS sorted for GFP-
expression and expanded. In addition to bulk cultures, we also
pooled multiple high GFP expressing clones to obtain sufficient
expression levels. Expression was verified by Western blotting and
real-time RT-PCR.
RNA Isolation and Reverse Transcription
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). A total amount of 1 mg of RNA from each
sample was reverse-transcribed using random primers and MMLV
reverse transcriptase according to the manufacturer’s protocol
(Promega, Madison, Wisconsin, USA).
Gene Expression Analyses by Quantitative Real-time RT-
PCR
For quantitative real-time RT-PCR, cDNA was amplified in an
ABI Prism 7700 sequence detector (Applied Biosystems, Foster
City, CA, USA). EPHB6 was detected with the following primers
and probe: forward (59-TGGACTATCAGCTCCGCTAC-
TATG), reverse (59- GTGGCAGTGTTGGTCTCGC) and
probe (59-FAM- CCAGGCAGAAGACGAATCCCACTCCTT-
TAMRA). The relative amounts of gene expression were
calculated by using the expression of GAPDH as an internal
standard.
Western Blot Analysis
Proteins were detected using the following antibodies: anti-
human EPHB6 (1 mg/ml, Abnova Corporation, Neihu, Taipei,
Taiwan, or ABGENT, San Diego, CA, USA) and b-actin (40 ng/
ml, Sigma, USA) as primary antibodies, Goat anti-mouse and
Goat anti-rabbit (both from Dianova, Hamburg, Germany) as
secondary antibodies. Western blot analysis was carried out as
described [23]. The See Blue Plus2 protein marker (Invitrogen) was
used as a size indicator.
Boyden Chamber Assay
A total of 56105 A549 cells (in 100 ml DMEM with 5% FCS)
were seeded into the upper part of a TranswellH chamber
Figure 1. EPHB6 mutants and functional domains. A) Functional domains of the EPHB6 gene are shown in relation to their exons and to
identified mutations for EPHB6. The description of the mutations correspond to their localization on the protein sequence. The mutations R52C,
Q498H, and DPG915-917del were identified in NSCLC patient samples in current study. B) Electropherogram of the EPHB6-wildtype sequence and the
deletion mutant for EPHB6. C) Expression levels of EPHB6-mutants in transfected cells. Bulk transfected cells were GFP sorted and expanded in
selection media. Expression levels are shown for bulk cultures with .90% GFP expression. Differences of expression analysis between protein levels
and mRNA levels are shown. For quantitative real-time PCR the average and standard deviation of three independent experiments are shown. The
western blot shows a representative example.
doi:10.1371/journal.pone.0044591.g001
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(transwell filter inserts in 6.5 mm diameter with a pore size of
5 mm, Corning Inc., Corning, NY), which was 30 min precoated
with 50 mg fibronectin. In the lower part of the chamber 600 ml
DMEM medium with 20% FCS (a serum gradient was used as
chemoattractant) was added and the assay was performed for 16
hours at 37uC and 5% CO2 before migrated cells were analyzed
by flow cytometry. All assays were repeated four times and
independently performed in triplicates.
In vitro Wound Healing – Scratch Assay
A549 cells were seeded in a 25-mL tissue culture flask at
a density of 350,000 cells per flask and were cultured over
a period of three days. Confluent cell monolayers were then
scratched using a 10 mL-pipette tip. The medium was
exchanged and the wound healing was registered by live video
microscopy. Images were captured in 106min intervals for 17 h
using a ZEISS (light) microscope Axiovert 40C, linked to a CCD
video camera (Hamamatsu). Image acquisition was controlled by
HiPic 32 (High Performance Image Control System) or
WASABI (Hamamatsu Imaging Software). The analysis of the
wound healing was performed using the Java-based image
processing program ImageJ. Assays were performed indepen-
dently for three times.
Figure 2. Migration analysis of EPHB6 expressing NSCLC cells. A) Protein expression of stably transfected A549 cell lines expressing wild type
EPHB6 or the EPHB6 deletion mutant. Cells were co-transfected using an EGFP -pcDNA3.1+ vector for identification of selected clones. Multiple clones
were pooled and further selected as bulk cultures. B) Transwell migration assays were performed with empty vector control cells, EPHB6 mutant and
EPHB6 wildtype cells. Five different experiments in triplicates were analyzed. *: significant (p,0.05) differences by (EITHER ANOVA OR t-test) The
provided p-value between the three different cell lines was statistically analyzed from all migrated cells by using the OneWay ANOVA-test. The
analysis of the pair-wise t-test results in a significant p-value for the control cells vs. EPHB6-wt cells (p,0.015) and between the EPHB6-wt cells and
the EPHB6-mut cells (p,0.005). C) In vitro wound healing scratch assay. Cells were scratched by a 10 ml pipette tip. The scratch areas were recorded
over a periode of 17 hours. Shown are means of three different experiments, calculated as percentage from one initial point for all three cell lines. The
ANOVA-test (p,0.002) indicated statistically significant differences between the three cell lines. D) Representative images of the scratch assays at the
beginning and the end of the experiments.
doi:10.1371/journal.pone.0044591.g002
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Analysis of the Cell Size
A549 cells expressing EPHB6-wild type, the EPHB6-mutant or
low EPHB6 (control/empty vector transduced) were seeded into
cell culture flasks which were precoated with a collagen matrix.
The cells were allowed to adhere for five hours and then
monitored using a ZEISS (light) microscope Axiovert 40C, linked
to a CCD video camera (Hamamatsu). Image acquisition was
controlled by HiPic 32 (High Performance Image Control System)
or WASABI (Hamamatsu Imaging Software). The analysis of the
cell size of single cells was performed as described previously [24],
using the visualization software Amira and the Java-based image
processing program ImageJ. The software analyze parameters of
cellular functions from single cells, including the determination of
the cell area (in mm2).
Metastasis Experiments in vivo
For all mouse experiments, we used 8 to 10 weeks old
NOD.CB17-Prkdc,scid./J (NOD/SCID) mice obtained from
Charles River. To analyze metastasis development upon in-
travenous tumor cell injection, 22 NOD/SCID mice were
irradiated with a single dose of 3.5 Gy from a cobalt-60 unit 1
day before transplantation. A total of 36105 stably transfected cells
(dissolved in 200 ml PBS) were injected intravenously into the tail
vein. Four weeks after transplantation, the mice were sacrificed
and the development of lung metastasis was analyzed. In two
cases, mice died within one week after transplantation: one mouse
transplanted with EPHB6-wt expressing A549 cells and one mouse
transplanted with EPHB6-mutant expressing A549 cells. Metas-
tasis development was evaluated by counting individual metastatic
nodules. For histological analyses, the lungs were fixed in 4%
paraformaldehyde. In all experiments, treatment groups were
randomized to prevent cage effects.
Statistical Analysis
All experimental data are shown as mean plus standard
deviation if not indicated otherwise. The mean values of three
groups were compared by OneWay ANOVA from Raw data or in
case of two groups by the students t-test. A two-sided p,0.05 was
considered significant.
Figure 3. Development of metastasis in vivo. A) Number of pulmonary metastases in evaluable NOD/SCID mice four weeks after transplantation,
each with 36105 stably transfected A549 cells expressing EPHB6-wt (n = 9), EPHB6-del915-917 (n = 9) or empty vector control cells (n = 2). Dots
represent individual mice and horizontal lines the median value of metastases. B) Images from representative whole lungs of NOD/SCID mice,
transplanted with A549 cells expressing EPHB6-wt, EPHB6-del915-917, or empty vector control. Lung metastases are marked by black arrows. C)
Images from lung sections of NOD/SCID mice, stained with hematoxylin. Metastases are marked by black arrows. Three representative examples are
shown each for mice transplanted with A549 cells expressing EPHB6-wt or EPHB6-del915-917.
doi:10.1371/journal.pone.0044591.g003
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Results
EPHB6 Variants in NSCLC
All exons of the entire coding region of EPHB6 were sequenced
by Sanger based sequencing in a cohort of NSCLC patients.
Among 80 NSCLC patients, three (3.8%) cases were found to have
non-synonymous mutations of EPHB6 (R52C, n= 1; Q498H,
n= 1; and DPG915-917del, n = 1). No EPHB6 mutations were
identified in the cell lines A549, HTB56 or HTB58. A
bioinformatics analysis by SIFT and Polyphen indicated the point
mutations R52C and Q498H as probably damaging (Table 1). A
database search of recent large scale sequencing efforts revealed
additional mutations that so far have not been further investigated
(Fig. 1A).
EPHB6 mutations were identified in various exons and
functional domains of the gene. Intriguingly, the deletion
del915-917 (Fig. 1B) was located adjacent to two mutations
(D915G and G914V) recently identified in patients with colorectal
cancer [25,26]. The cluster of mutations in this region between the
tyrosine kinase catalytic (Tyrkc) domain and sterile alpha motif
(SAM) further suggests functional relevance. This mutation was
identified in a patient with lung adenocarcinoma. The mutation
was heterozygous and was also detected in corresponding normal
lung tissue indicating a germline mutation. The other mutations
were solely detected in the tumor and not in matched healthy
tissue inficating a somatic mutation.
For functional assays, EPHB6-wildtype and several mutants
(R52C, Q498H, del915-917 and the P728S mutation previously
described in ovarian cancer [LIT]) were stably co-transfected with
an EGFP-expressing plasmids into the NSCLC-cell line A549 that
expresses very low levels of EPHB6. EGFP positive clones were
picked and expression analysis was performed by western blotting
using EPHB6 antibody on single clones and on bulk cultures
(Fig. 2A). Despite successful transfection with increased mRNA
levels, protein expression of most of the EPHB6 mutants did not
increase beyond the levels observed in empty vector transfected
cells (Fig. 1C). Only for the del915-917 mutation, protein
expression at levels similar to EPHB6 wildtype was achieved
(Fig. 2A). Due to the insufficiency of adequate protein expression
of the R52C and G498H mutants and the previously described
P728S mutant, we functionally focused on the del915-917
mutation in NSCLC in subsequent experiments.
Effects of EPHB6 Mutations on Migration and Metastasis
of NSCLC Cells
As reported, EPHB6 wildtype inhibited migration of stably
transfected A549 cells in a transwell chamber (Boyden chamber)
assay. In contrast, cells transfected with the del915-917 mutant
EPHB6 migrated significantly faster in this assay (Fig. 2B). In
addition, we performed scratch assays with repeated video
microscopy to follow the scratch closure over time. Wildtype
EPHB6 inhibited in vitro wound healing compared to the empty
vector, whereas the EPHB6 mutant cells closed the gap much
faster than the wildtype (three independent experiments, p,0.002,
ANOVA; p,0.0004, t-test) (Fig. 2C, D). It appeared that the
EPHB6 mutant did not just inhibit the EPHB6 wildtype activity,
but accelerated the closing of the wound compared to empty
vector and wildtype. After eight hours of adherence, the open area
of the EPHB6 mutant cells starts to decrease two times (3%) faster
as it could be recognized for the EPHB6 wildtype cells (1.6%).
Even the control cells showed less acceleration of wound closure
(2%) at this time point.
To analyze the in vivo effects of EPHB6 mutations on the
metastatic capacity of NSCLC cells, we performed in vivo
metastasis assays. NOD/SCID mice were intravenously injected
with EPHB6-wt cells (n = 10), EPHB6-del915-917 cells (n = 10)
and empty vector control cells (n = 2). Four weeks after trans-
plantation mice were sacrificed and analyzed. One mouse of each
group of mice transplanted with EPHB6-wt and EPHB6-mut
expressing cells died within one week after transplantation. Mice
injected with EPHB6 wild type overexpressing cells showed lower
numbers of lung metastases compared to mice injected with either
Figure 4. Proliferative activity and cell size of EPHB6 wildtype and mutant cells. A) Proliferative activity of empty vector control, EPHB6
wildtype and mutant cells were analyzed using a colorimetric MTT assay after 72 hours. Data are shown as means +/2 standard deviation of three
independent experiments. Differences were statistically not significant (ANOVA). B) Cell size of individual cells (n = 20) growing on plastic dishes was
analyzed by live video microscopy and recorded. EPHB6 mutant cells showed a significantly reduced cell size in comparison to EPHB6 wild type and
to control cells (p,0.05, t-test).
doi:10.1371/journal.pone.0044591.g004
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empty vector control cells or EPHB6-mutant cells (Fig. 3): one
mouse was found without metastasis, 2 mice with each 1 or 3
metastasis and one mouse with each 4, 5 or 8 metastasis. One
mouse transplanted with EPHB6 wild type cells was found with
a high number of lung metastasis. Interestingly, in all mice injected
with EPHB6 mutant cells lung metastasis were detectable (Fig. 3;
p = 0.011, t-test of data from mice transplanted with EPHB6-wt
compared to EPHB6-mut cells). An in vitro proliferation assay after
72 hours (Fig. 4A) showed that EPHB6 mutant cells did not differ
from EPHB6 wildtype expressing cells in terms of proliferative
activity. Similar results were obtained in proliferation assays
analyzed after 48 hours (data not shown). The experiments rather
suggested that the increased metastatic activity in vivo was
associated with the alteration of intrinsic migratory properties.
EPHB6 wildtype receptor expression did not significantly change
the shape of cells (although the variation of shape size increased)
whereas the size of EPHB6 mutant cells that grew on regular
plastic dishes was significantly diminished (Fig. 4B; p,0.05, t-test
of data from 20 cells of EPHB6-wt and EPHB6-mut expressing
cells). In line with these findings, the chemotaxis of EPHB6 cells on
plastic dishes appeared to be reduced, most likely due to reduced
adhesion properties. But the differences were statistically not
significant (data not shown).
Discussion
Ephrin – Eph receptor interactions are frequently deregulated
in cancer (Reference). In current study we identified mutations of
EPHB6 as a pro-metastatic feature in non-small cell lung cancer.
One mutation, del915-917, was also present in matched normal
tissue, strongly suggesting a germline alteration. Germline
alterations have previously been described for EPHB6 in familial
colorectal cancer To date, the functional consequences of these
genetic alterations on a cellular level are unknown [25].
Alterations of Eph receptors frequently occur in lung cancer.
One large scale sequencing study found mutations in 10 out of
13 Eph receptor genes in lung adenocarcinoma [27]. Due to the
multiplicity of Eph receptor associated signaling events and the
complex networking of receptors, the functional outcome of Eph
receptor aberrations remain unclear [28]. For most of the Eph
receptor alterations identified to date, functional consequences
have not been studied.
Several somatic mutations of the EPHB6 gene have been
previously identified in lung cancer [27], colorectal cancer [25,26],
ovarian cancer [29] and glioma [26].
In this study, screening of 80 NSCLC patient samples and 3
NSCLC cell lines identified 3 previously unknown mutations for
the EPHB6 gene. One of this mutations, del915-917, resides in the
domain between the tyrosine kinase and the sterile alpha motif
(SAM) domain, where 2 somatic mutations were recently
identified in colorectal cancer [25,26]. The function of this
domain is suggested to be related to cancer, and our findings in
this work do support this suggestion. The in vivo experiments show
clearly that expression of the mutated EPHB6 enhanced
metastasis. In addition EPHB6-mutant expressing cells showed
a threefold enhanced transwell migration towards a serum
gradient (chemotaxis). These results are consistent with our in vivo
results. Mice transplanted with EPHB6-mut cells developed
significantly (p = 0.011) more lung metastases as mice transplanted
with EPHB6-wt cells. In addition to the altered functions of the
EPHB6 del(915-917) mutant, a few aspects might also suggest
a gain of function. For example, the patterns of wound healing
differed between EPHB6 wildytpe and mutant. It is possible that
signaling differences exist between the wildtype and the mutant
receptor. On the other hand, it might also be interesting to
speculate that the mutant receptor might act dominant negative
towards other inhibitory EPH receptors. This dominant negative
activity might lead to the observation of potential gain of function
potency. Clearly, future studies might reveal the underlying
differences in signaling and the influence of other member of the
EPH and EPH-receptor networks. Future studies might also reveal
the functional effects of the non-del915-917 mutations. It is likely
that these also inactivate EPHB6 but this needs to be confirmed in
the future.
Recently, we could demonstrate that EPHB6 is frequently
silenced by epigenetic mechanisms in lung cancer [21], and others
could show the same inactivation mechanism in breast cancer
[14]. Our studies also indicated that loss of EPHB6 induces
a highly metastatic phenotype. In line, EPHB6 is the receptor
tyrosine kinase for which low expression was most closely related
with poor prognosis in early stage non-small cell lung cancer [20].
EPHB6 might play an important role in lung cancer metastasis
given that it is frequently epigenetically silenced and/or mutated
in a significant fraction of patients. This makes it possible that
EPHB6 is a relevant modifier of metastatic capacity in lung
cancer.
Taken together, mutations in EPHB6 occurring in non-small
cell lung cancer might lead towards a pro-metastatic phenotype.
Loss of EPHB6 function by decreased expression or mutational
inactivation might therefore contribute to lung cancer metastasis.
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